Rhythm Pharmaceuticals' Setmelanotide Shows Strong Results in Hypothalamic Obesity Trial — Rhythm Pharmaceuticals, Inc.

Event summary

Rhythm Pharmaceuticals published Phase 3 TRANSCEND trial results in The New England Journal of Medicine, showing setmelanotide reduced BMI by 16.5% in patients with acquired hypothalamic obesity.
The trial involved 120 patients and demonstrated an 80% response rate for BMI reduction of 5% or greater at 52 weeks.
Setmelanotide received FDA approval and EMA recommendation for treating acquired hypothalamic obesity in March 2026.

The big picture

Rhythm Pharmaceuticals' positive Phase 3 results for setmelanotide in acquired hypothalamic obesity mark a significant milestone in treating rare neuroendocrine diseases. The FDA and EMA approvals underscore the therapeutic potential of targeting the MC4R pathway, positioning Rhythm as a leader in this niche but growing segment of the biopharmaceutical industry.

What we're watching

Regulatory Expansion: Whether Rhythm can secure additional global approvals for setmelanotide, particularly in Japan.
Market Penetration: The pace at which Rhythm can commercialize setmelanotide for acquired hypothalamic obesity and other rare neuroendocrine diseases.
Clinical Development: How the success of setmelanotide will influence the development of Rhythm’s broader pipeline, including bivamelagon and RM-718.